Home / ARDS : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ARDS make money? Does ARDS have pricing power? What's the Earnings Whisper? Will ARDS profit more as the business scales? What is ARDS's management track record? Is ARDS's current price justified?

Aridis Pharmaceuticals, Inc.

$0 -$0.00 (-50.00%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

Day Range

$0$0

Year Range

$0$0.05

Market Cap

4.46K

AVG Volume

14.42K

Trailing/Forward PE

-0/0

PEG ratio

-0

Dividend Yield

Next Earnings Date

2026-11-02

Primary Exchange

Other OTC

Revenue (USD)

ARDS Revenue (USD) by year
Period	Revenue (USD)
2022	292K
2021	701K
2020	1M
2019	0
2018	2.76M
2017	926K

Net Income (USD)

ARDS Net Income (USD) by year
Period	Net Income (USD)
2022	-31.78M
2021	-43.61M
2020	-22.33M
2019	-29.68M
2018	-22.11M
2017	-24.66M

Operating Income (USD)

ARDS Operating Income (USD) by year
Period	Operating Income (USD)
2022	-29.99M
2021	-44.13M
2020	-22.4M
2019	-29.09M
2018	-24.12M
2017	-19.74M

EBITDA (USD)

ARDS EBITDA (USD) by year
Period	EBITDA (USD)
2022	-29.51M
2021	-42.71M
2020	-22.06M
2019	-28.75M
2018	-23.83M
2017	-19.68M

Cash Flows (USD)

ARDS Cash Flows (USD) by year
Period	Cash Flows (USD)
2022	-29.21M
2021	-23.47M
2020	-20.84M
2019	-8.33M
2018	-24.03M
2017	-18.25M

EPS (USD)

ARDS EPS (USD) by year
Period	EPS (USD)
2022	-1.78
2021	-3.56
2020	-2.44
2019	-3.52
2018	-3.75
2017	-3.13

Expenses (USD)

ARDS Expenses (USD) by year
Period	Expenses (USD)
2022	33.17M
2021	45.78M
2020	23.77M
2019	30.28M
2018	26.63M
2017	21.3M

Cash & Debt (USD)

ARDS Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2022	4.88M
2021	19.99M
2020	8.23M
2019	20.9M
2018	24.24M
2017	25.1M

Debt ratios

ARDS Debt ratios by year
Period	Debt ratios
2022	-0.01
2021	0.12
2020	0.08

Margins

ARDS Margins by year
Period	Margins
2022	100%
2021	100%
2020	100%
2018	100%
2017	100%

Return on Capital

ARDS Return on Capital by year
Period	Return on Capital
2022	131.16%
2021	309.07%
2020	257.26%
2019	-816.31%
2018	-84%
2017	-215.61%

Shares Outstanding

ARDS Shares Outstanding by year
Period	Shares Outstanding
2022	18.24M
2021	14.5M
2020	9.9M
2019	8.91M
2018	8.1M
2017	7.89M

Book Value Per Share (USD)

ARDS Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2022	-1.33
2021	-0.97
2020	-0.88
2019	0.41
2018	3.25
2017	1.45

Total Assets (USD)

ARDS Total Assets (USD) by year
Period	Total Assets (USD)
2022	14.7M
2021	26.8M
2020	15.12M
2019	27.97M
2018	31.61M
2017	26.48M

Employee Count

ARDS Employee Count by year
Period	Employee Count
2022	37
2021	34
2020	33
2019	25
2018	23

Free Cash Flow Yield

ARDS Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-479147.92%
Sep 26	-479147.93%
Aug 26	-479147.92%
Aug 26	-479147.93%
Aug 26	-479147.93%
Aug 26	-479147.93%
Jul 26	-479147.93%
Jul 26	-479147.93%
Jul 26	-479147.92%
Jul 26	-479147.92%
Jul 26	-479147.93%
Jun 26	-119786.98%
Jun 26	-15456.38%
Jun 26	-239573.96%
Jun 26	-239573.96%
May 26	-239573.96%
May 26	-29039.27%
May 26	-239573.96%
May 26	-239573.96%
May 26	-239573.96%
Apr 26	-239573.96%
Apr 26	-239573.96%
Apr 26	-239573.96%
Apr 26	-239573.96%
Mar 26	-239573.96%
Mar 26	-239573.96%
Mar 26	-239573.96%
Mar 26	-239573.96%
Feb 26	-26619.33%
Feb 26	-239573.96%
Feb 26	-239573.96%
Feb 26	-239573.96%
Jan 26	-239573.96%
Jan 26	-239573.96%
Jan 26	-19557.06%
Jan 26	-159715.97%
Jan 26	-239573.96%
Dec 25	-239573.96%
Dec 25	-239573.96%
Dec 25	-239573.96%
Dec 25	-239573.96%
Nov 25	-239573.96%
Nov 25	-23373.07%
Nov 25	-239573.96%
Nov 25	-33044.68%
Oct 25	-239573.96%
Oct 25	-33044.68%
Oct 25	-239573.96%
Oct 25	-20832.52%
Oct 25	-239573.96%
Sep 25	-28185.17%
Sep 25	-239573.96%
Sep 25	-239573.96%
Sep 25	-95829.58%
Aug 25	-479147.93%
Aug 25	-479147.93%
Aug 25	-479147.93%
Aug 25	-479147.93%
Aug 25	-479147.93%
Jul 25	-479147.93%
Jul 25	-479147.93%
Jul 25	-479147.93%
Jul 25	-479147.93%
Jun 25	-479147.93%
Jun 25	-479147.93%
Jun 25	-479147.93%
Jun 25	-479147.93%
May 25	-479147.93%
May 25	-239573.96%
May 25	-479147.93%
May 25	-479147.93%
May 25	-479147.93%
Apr 25	-479147.93%
Apr 25	-479147.93%
Apr 25	-479147.93%
Apr 25	-479147.93%
Mar 25	-479147.93%
Mar 25	-479147.93%
Mar 25	-479147.93%
Mar 25	-479147.93%
Feb 25	-479147.93%
Feb 25	-479147.93%
Feb 25	-479147.93%
Feb 25	-479147.93%
Jan 25	-47914791.5%
Jan 25	-479147.93%
Jan 25	-479147.93%
Jan 25	-479147.93%
Jan 25	-479147.92%
Dec 24	-479147.92%
Dec 24	-479147.92%
Dec 24	-479147.92%
Dec 24	-239573.96%
Nov 24	-479147.92%
Nov 24	-479147.93%
Nov 24	-479147.93%
Nov 24	-239573.96%
Nov 24	-239573.96%
Oct 24	-479147.92%
Oct 24	-479147.93%

Price to Sales

ARDS Price to Sales by year
Period	Price to Sales
Sep 26	0
Sep 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jun 26	0
Jun 26	0.01
Jun 26	0
Jun 26	0
May 26	0
May 26	0
May 26	0
May 26	0
May 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Feb 26	0
Feb 26	0
Feb 26	0
Feb 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Dec 25	0
Dec 25	0
Dec 25	0
Dec 25	0
Nov 25	0
Nov 25	0
Nov 25	0
Nov 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Jul 25	0
Jul 25	0
Jul 25	0
Jul 25	0
Jun 25	0
Jun 25	0
Jun 25	0
Jun 25	0
May 25	0
May 25	0
May 25	0
May 25	0
May 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Feb 25	0
Feb 25	0
Feb 25	0
Feb 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Dec 24	0
Dec 24	0
Dec 24	0
Dec 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Oct 24	0
Oct 24	0

Price to Book

ARDS Price to Book by year
Period	Price to Book
May 20	21.99
May 20	14.78
Apr 20	15.62
Apr 20	14.76
Apr 20	15.32
Apr 20	5.65
Mar 20	5.76
Mar 20	5.52
Mar 20	5.2
Mar 20	6.31
Feb 20	6.68
Feb 20	7.32
Feb 20	5.78
Feb 20	6.26
Jan 20	6.84
Jan 20	7.54
Jan 20	7.34
Jan 20	7.02
Jan 20	4.66
Dec 19	4.16
Dec 19	4.16
Dec 19	4.57
Dec 19	5
Nov 19	5.45
Nov 19	5.06
Nov 19	4.51
Nov 19	3.85
Nov 19	4.04
Oct 19	4.16
Oct 19	4.55
Oct 19	4.25
Oct 19	5.05
Sep 19	4.9
Sep 19	5.53
Sep 19	6.4
Sep 19	8.49
Aug 19	8.72
Aug 19	6.16
Aug 19	5.78
Aug 19	3.65
Aug 19	3.66
Jul 19	4.09
Jul 19	4.25
Jul 19	4.22
Jul 19	4.46
Jun 19	4.41
Jun 19	4.91
Jun 19	3.1
Jun 19	3.97
May 19	3.77
May 19	4.04
May 19	4.07
May 19	2.84
May 19	2.98
Apr 19	3.08
Apr 19	2.97
Apr 19	3.12
Apr 19	3.48
Mar 19	3.51
Mar 19	1.49
Mar 19	1.2
Mar 19	1.14
Mar 19	1.11
Feb 19	1.11
Feb 19	1.08
Feb 19	1.1
Feb 19	1.04
Jan 19	1.11
Jan 19	1.15
Jan 19	1.23
Jan 19	1.28
Dec 18	1.32
Dec 18	1.02
Dec 18	1.23
Dec 18	1.09
Nov 18	1.36
Nov 18	1.53
Nov 18	1.62
Nov 18	43.66
Nov 18	44.22
Oct 18	44.66
Oct 18	45.2
Oct 18	45.91
Oct 18	46.52
Sep 18	47.21
Sep 18	25.02
Sep 18	24.82
Sep 18	25.25
Aug 18	28.02
Aug 18	27.16
Aug 18	26.93

No video analysis for this stock yet. Request one from our team.

News: ARDS

gurufocus.com · 13 Sep 2026

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi

AI Analysis

Aridis Pharmaceuticals, Inc.

Video analysis: ARDS

News: ARDS

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Similar companies